{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T15:34:36Z","timestamp":1771256076936,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1038\/s41433-022-02091-6","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T14:03:50Z","timestamp":1652969030000},"page":"1214-1218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Choroidal modifications assessed by means of choroidal vascularity index after oral eplerenone treatment in chronic central serous chorioretinopathy"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5311-5184","authenticated-orcid":false,"given":"Lisa","family":"Toto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Ludovica","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Viggiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5383-5173","authenticated-orcid":false,"given":"Rossella","family":"D\u2019Aloisio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"De Nicola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennaro","family":"Falconio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Di Nicola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"Porreca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo","family":"Mastropasqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"2091_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ophtha.2007.02.032","volume":"115","author":"AS Kitzmann","year":"2008","unstructured":"Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burkel JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmol. 2008;115:169\u201373.","journal-title":"Ophthalmol"},{"key":"2091_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/aos.12779","volume":"94","author":"KH Wong","year":"2016","unstructured":"Wong KH, Lau KP, Chhablani J, Tao Y, Li Q, Wong IY. Central serous chorioretinopathy: what we have learnt so far. Acta Ophtalmol. 2016;94:321\u20135.","journal-title":"Acta Ophtalmol"},{"key":"2091_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/tvst.5.2.2","volume":"5","author":"A Daruich","year":"2016","unstructured":"Daruich A, Matet A, Dirani A, Gallice M, Nicholson L, Sivaprasad S, et al. Oral mineralocorticoid-receptor antagonists: real-life experience in clinical subtypes of nonresolving central serous chorioretinopathy with chronic epitheliopathy. Transl Vis Sci Technol. 2016;5:2.","journal-title":"Transl Vis Sci Technol"},{"key":"2091_CR4","first-page":"14","volume":"33","author":"CMG Cheung","year":"2019","unstructured":"Cheung CMG, Lee WK, Koizumi H, Dansingani K, Lai TYY, Freund KB. Pachychoroid disease. Eye(Lond). 2019;33:14\u201333.","journal-title":"Eye(Lond)"},{"key":"2091_CR5","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1172\/JCI61427","volume":"122","author":"M Zhao","year":"2012","unstructured":"Zhao M, C\u00e9l\u00e9rier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012;122:2672\u20139.","journal-title":"J Clin Invest"},{"key":"2091_CR6","doi-asserted-by":"publisher","first-page":"474","DOI":"10.3390\/jcm8040474","volume":"7","author":"L Toto","year":"2019","unstructured":"Toto L, D\u2019Aloisio R, Mastropasqua R, Di Antonio L, Di Nicola M, Di Martino G, et al. Anatomical and functional changes of the retina and the choroid after resolved chronic CSCR. J Clin Med. 2019;7;8:474.","journal-title":"J Clin Med."},{"key":"2091_CR7","doi-asserted-by":"publisher","first-page":"4864","DOI":"10.2174\/1381612825666190123165914","volume":"24","author":"P Iacono","year":"2018","unstructured":"Iacono P, Toto L, Eliana C, Varano M, Parravano MC. Pharmacotherapy of central serous chorioretinopathy: review of the current treatments. Curr Pharm Des. 2018;24:4864\u201373.","journal-title":"Curr Pharm Des"},{"key":"2091_CR8","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(19)32981-2","volume":"395","author":"A Lotery","year":"2020","unstructured":"Lotery A, Sivaprasad S, O\u2019 Connell A, Harris RA, Culliford L, Ellis L, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;395:294\u2013303.","journal-title":"Lancet"},{"key":"2091_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S0140-6736(19)33132-0","volume":"25","author":"A Rabiolo","year":"2020","unstructured":"Rabiolo A, Bandello F. Eplerenone is not superior to placebo for chronic central serous chorioretinopathy. Comment. Lancet. 2020;25;395:252\u20133.","journal-title":"Lancet"},{"key":"2091_CR10","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/S0140-6736(20)31610-X","volume":"396","author":"R Sacconi","year":"2020","unstructured":"Sacconi R, Borrelli E, Querques G. Eplerenone for chronic central serous chorioretinopathy. Lancet. 2020;396:1556.","journal-title":"Lancet"},{"key":"2091_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(19)32981-2","volume":"395","author":"A Lotery","year":"2020","unstructured":"Lotery A, Sivaprasad S, O\u2019Connell A, Harris RA, Culliford L, Ellis L, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Randomized Controlled Trial. Lancet. 2020;395:294\u2013303.","journal-title":"Lancet"},{"key":"2091_CR12","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1136\/bjophthalmol-2018-312892","volume":"103","author":"M Zola","year":"2019","unstructured":"Zola M, Daruich A, Matet A, Mantel I, Behar-Cohen F. Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy. Br J Ophtalmol. 2019;103:1184\u20139.","journal-title":"Br J Ophtalmol"},{"key":"2091_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00417-019-04524-7","volume":"258","author":"J Yang","year":"2020","unstructured":"Yang J, Wang E, Yuan M, Chen Y. Three-dimensional choroidal vascularity index in acute central serous chorioretinopathy using swept-source optical coherence tomography. Graefes Arch Clin Exp Ophtalmol. 2020;258:241\u20137.","journal-title":"Graefes Arch Clin Exp Ophtalmol"},{"key":"2091_CR14","first-page":"12885","volume":"97","author":"E Yumusak","year":"2018","unstructured":"Yumusak E, Buyuktortop Gokcinar N, Ornek K. Choroidal thickness changes in non-treated acute and ranibizumab-treated chronic central serous chorioretinopathy. Observational Study. 2018;97:12885.","journal-title":"Observational Study"},{"key":"2091_CR15","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.ajo.2015.01.006","volume":"159","author":"S Manabe","year":"2015","unstructured":"Manabe S, Shiragami C, Hirooka K, Izumibata S, Tsujikawa A, Shiraga F. Change of regional choroid thickness after reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy. Am J Ophthalmol. 2015;159:644\u201351.","journal-title":"Am J Ophthalmol"},{"key":"2091_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/bjophthalmol-2016-308921","volume":"101","author":"T Izumi","year":"2017","unstructured":"Izumi T, Koizumi H, Maruko I, Takahashi Y, Sonoda S, Sakamoto T, et al. Structural analyses of choroid after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy. Br J Ophthalmol. 2017;101:433\u20137.","journal-title":"Br J Ophthalmol"},{"key":"2091_CR17","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.ajo.2015.03.005","volume":"159","author":"S Sonoda","year":"2015","unstructured":"Sonoda S, Sakamoto T, Yamashita T, Uchino E, Kawano H, Yoshihara N, et al. Luminal and stromal areas of choroid determined by binarization method of optical coherence tomographic images. Am J Ophthalmol. 2015;159:1123\u201331.","journal-title":"Am J Ophthalmol"},{"key":"2091_CR18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3390\/jcm9020595","volume":"9","author":"C Iovino","year":"2020","unstructured":"Iovino C, Pellegrini M, Bernabei F, Borrelli E, Sacconi R, Govetto A, et al. Choroidal vascularity index: an in-depth analysis of this novel optical coherence tomography parameter. J Clin Med. 2020;9:595.","journal-title":"J Clin Med"},{"key":"2091_CR19","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00417-020-04619-6","volume":"258","author":"TJ Van Rijssen","year":"2020","unstructured":"Van Rijssen TJ, Singh SR, Dijk EHC, Rasheed MA, Vupparaboina KK, Boon CJF, et al. Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophtalmol. 2020;258:1191\u20137.","journal-title":"Graefes Arch Clin Exp Ophtalmol"},{"key":"2091_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3341\/kjo.2019.0063","volume":"33","author":"JH Kwak","year":"2019","unstructured":"Kwak JH, Hong S, Ra H, Kim EC, Kang NY, Baek J. Effect of acetazolamide on choroidal morphology in central serous chorioretinopathy. Korean J Ophtalmol. 2019;33:493\u20139.","journal-title":"Korean J Ophtalmol"},{"key":"2091_CR21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.survophthal.2018.11.002","volume":"64","author":"SR Singh","year":"2019","unstructured":"Singh SR, Vupparaboina KK, Goud A, Dansingani KK, Chhablani J. Choroidal imaging biomarkers. Surv Ophthalmol. 2019;64:312\u201333.","journal-title":"Surv Ophthalmol"},{"key":"2091_CR22","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/IAE.0000000000002459","volume":"40","author":"G Giannaccare","year":"2020","unstructured":"Giannaccare G, Pellegrini M, Sebastiani S, Bernabei F, Moscardelli F, Claudio Iovino, et al. Choroidal vascularity index quantification in geographic atrophy using binarization of enhanced-depth imaging optical coherence tomographic scans. Retina. 2020;40:960\u20135.","journal-title":"Retina"},{"key":"2091_CR23","doi-asserted-by":"crossref","unstructured":"Viggiano P, Toto L, Ferro G, Evangelista F, Porreca A, Mastropasqua R Choroidal structural changes in different intermediate AMD patterns. Eur J Ophtalmol. 1120672121992009 (2021).","DOI":"10.1177\/1120672121992009"},{"key":"2091_CR24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","volume":"48","author":"A Daruich","year":"2015","unstructured":"Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, et al. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015;48:82\u2013118.","journal-title":"Prog Retin Eye Res"},{"key":"2091_CR25","doi-asserted-by":"publisher","first-page":"9618","DOI":"10.3390\/ijms22179618","volume":"22","author":"J Canonica","year":"2021","unstructured":"Canonica J, Zhao M, Favez T, Geliz\u00e9 E, Jonet L, Kowalczuk L, et al. Pathogenic effects of mineralocorticoid pathway activation in retinal pigment epithelium. Int J Mol Sci. 2021;22:9618.","journal-title":"Int J Mol Sci"},{"key":"2091_CR26","doi-asserted-by":"publisher","first-page":"107747","DOI":"10.1016\/j.exer.2019.107747","volume":"187","author":"J Canonica","year":"2019","unstructured":"Canonica J, Mehanna C, Bonnard B, Jonet L, Gelize E, Jais J-P, et al. Effect of acute and chronic aldosterone exposure on the retinal pigment epithelium-choroid complex in rodents. Exp Eye Res. 2019;187:107747.","journal-title":"Exp Eye Res"},{"key":"2091_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.preteyeres.2017.12.001","volume":"64","author":"A Reiner","year":"2018","unstructured":"Reiner A, Fitzgerald MEC, Del Mar N, Li C. Neural control of choroidal blood flow. Prog Retin Eye Res. 2018;64:96\u2013130.","journal-title":"Prog Retin Eye Res"},{"key":"2091_CR28","doi-asserted-by":"publisher","first-page":"e1375","DOI":"10.1111\/aos.14809","volume":"99","author":"M Gallice","year":"2021","unstructured":"Gallice M, Daruich A, Matet A, Mouvet V, Dirani A, Evequoz G, et al. Acta Ophthalmol. 2021;99:e1375\u2013e1381.","journal-title":"Acta Ophthalmol"},{"key":"2091_CR29","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1097\/IAE.0b013e31820f4b39","volume":"31","author":"I Maruko","year":"2011","unstructured":"Maruko I, Iida T, Sugano Y, Ojima A, Sekiryu T. Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy. Retina. 2011;31:1603\u20138.","journal-title":"Retina"},{"key":"2091_CR30","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/eye.2017.295","volume":"32","author":"R Sacconi","year":"2018","unstructured":"Sacconi R, Baldin G, Carnevali A, Querques L, Rabiolo A, Marchini G, et al. Response of central serous chorioretinopathy evaluated by multimodal retinal Imaging. Eye (Lond). 2018;32:734\u201342.","journal-title":"Eye (Lond)"},{"key":"2091_CR31","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1038\/eye.2014.219","volume":"28","author":"A Goktas","year":"2014","unstructured":"Goktas A. Correlation of subretinal fluid volume with choroidal thickness and macular volume in acute central serous chorioretinopathy. Eye (Lond). 2014;28:1431\u20136.","journal-title":"Eye (Lond)"},{"key":"2091_CR32","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1097\/IAE.0b013e3181be0a83","volume":"29","author":"Y Imamura","year":"2009","unstructured":"Imamura Y, Fujiwara F, Margolis R, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina. 2009;29:1469\u201373.","journal-title":"Retina"},{"key":"2091_CR33","first-page":"874","volume":"48","author":"Y Li-hong","year":"2012","unstructured":"Li-hong Y, Bei T, Xue-hui S, Ding N, Zhou D, Wei W. Changes of choroidal thickness in central serous chorioretinopathy. Zhonghua Yan Ke Za Zhi. 2012;48:874\u20137.","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"2091_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/srep21090","volume":"12","author":"R Agrawal","year":"2016","unstructured":"Agrawal R, Gupta P, Tan KA, Cheung CMG, Wong T, Cheng C. Choroidal vascularity index as a measure of vascular status of the choroid: Measurements in healthy eyes from a population-based study. Sci Rep. 2016;12;6:21090.","journal-title":"Sci Rep."},{"key":"2091_CR35","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1097\/IAE.0000000000001040","volume":"36","author":"R Agrawal","year":"2016","unstructured":"Agrawal R, Chhablani J, Tann KA. Choroidal vascularity index in central serous chorioretinopathy. Retina. 2016;36:1646\u201351.","journal-title":"Retina"},{"key":"2091_CR36","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.ophtha.2010.01.023","volume":"117","author":"I Maruko","year":"2010","unstructured":"Maruko I, Lida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF. Subfoveal choroidal thickness after treatment in central serous chorioretinopathy. Ophtalmol. 2010;117:1792\u20139.","journal-title":"Ophtalmol"},{"key":"2091_CR37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ajo.2009.04.010","volume":"148","author":"RF Spaide","year":"2009","unstructured":"Spaide RF, Koizumi H, Pozzonni MC. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophtalmol. 2009;148:325.","journal-title":"Am J Ophtalmol"},{"key":"2091_CR38","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1007\/s00417-019-04426-8","volume":"257","author":"W Park","year":"2019","unstructured":"Park W, Kim M, Kim RY, Park Y. Comparing effects of photodynamic therapy in central serous chorioretinopathy: full- dose versus half-dose versus half-dose-half-fluence. Graefes Arch Clin Exp Ophthalmol. 2019;257:2155\u201361.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2091_CR39","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/S0735-1097(02)02855-3","volume":"41","author":"S Kasama","year":"2003","unstructured":"Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. J Am Coll Cardiol. 2003;41:574\u201381.","journal-title":"J Am Coll Cardiol"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02091-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02091-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02091-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T16:08:20Z","timestamp":1681402100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-022-02091-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["2091"],"URL":"https:\/\/doi.org\/10.1038\/s41433-022-02091-6","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"assertion":[{"value":"1 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent statement"}}]}}